Get started
Ocular Therapeutix, Inc.Ocular Therapeutix, Inc.Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

OCUL chart


Full chart

OCUL upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.13 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.26 USD
Net income (FY)
‪−193.51 M‬ USD
Revenue (FY)
‪63.72 M‬ USD
Shares float
‪133.91 M‬
Beta (1Y)
1.71

Employees


Employees (FY)
274
Change (1Y)
+7 +2.62%
Revenue / Employee (1Y)
‪232.57 K‬ USD
Net income / Employee (1Y)
‪−706.23 K‬ USD

About Ocular Therapeutix, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Pravin U. Dugel
Website
ocutx.com
Headquarters
Bedford
Founded
2006
FIGI
BBG001J1BZV0
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

OCUL news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as OCUL.

Frequently Asked Questions


The current price of OCUL is 7.41 USD — it has increased by 6.47% in the past 24 hours. Watch Ocular Therapeutix, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Ocular Therapeutix, Inc. stocks are traded under the ticker OCUL.
OCUL stock has risen by 24.92% compared to the previous week, the month change is a −4.54% fall, over the last year Ocular Therapeutix, Inc. has showed a −4.88% decrease.
We've gathered analysts' opinions on Ocular Therapeutix, Inc. future price: according to them, OCUL price has a max estimate of 22.00 USD and a min estimate of 14.00 USD. Watch OCUL chart and read a more detailed Ocular Therapeutix, Inc. stock forecast: see what analysts think of Ocular Therapeutix, Inc. and suggest that you do with its stocks.
OCUL reached its all-time high on Mar 25, 2015 with the price of 44.19 USD, and its all-time low was 2.00 USD and was reached on Nov 10, 2023. View more price dynamics on OCUL chart.
See other stocks reaching their highest and lowest prices.
OCUL stock is 6.39% volatile and has beta coefficient of 1.71. Track Ocular Therapeutix, Inc. stock price on the chart and check out the list of the most volatile stocks — is Ocular Therapeutix, Inc. there?
Today Ocular Therapeutix, Inc. has the market capitalization of ‪1.20 B‬, it has decreased by −3.67% over the last week.
Yes, you can track Ocular Therapeutix, Inc. financials in yearly and quarterly reports right on TradingView.
Ocular Therapeutix, Inc. is going to release the next earnings report on May 12, 2025. Keep track of upcoming events with our Earnings Calendar.
OCUL earnings for the last quarter are −0.29 USD per share, whereas the estimation was −0.25 USD resulting in a −14.24% surprise. The estimated earnings for the next quarter are −0.29 USD per share. See more details about Ocular Therapeutix, Inc. earnings.
Ocular Therapeutix, Inc. revenue for the last quarter amounts to ‪17.08 M‬ USD, despite the estimated figure of ‪17.15 M‬ USD. In the next quarter, revenue is expected to reach ‪17.02 M‬ USD.
OCUL net income for the last quarter is ‪−48.39 M‬ USD, while the quarter before that showed ‪−36.49 M‬ USD of net income which accounts for −32.60% change. Track more Ocular Therapeutix, Inc. financial stats to get the full picture.
No, OCUL doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 15, 2025, the company has 274 employees. See our rating of the largest employees — is Ocular Therapeutix, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Ocular Therapeutix, Inc. EBITDA is ‪−168.00 M‬ USD, and current EBITDA margin is −263.63%. See more stats in Ocular Therapeutix, Inc. financial statements.
Like other stocks, OCUL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Ocular Therapeutix, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Ocular Therapeutix, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Ocular Therapeutix, Inc. stock shows the buy signal. See more of Ocular Therapeutix, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.